vs
Side-by-side financial comparison of BJs RESTAURANTS INC (BJRI) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $355.4M, roughly 2.0× BJs RESTAURANTS INC). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 3.6%, a 15.5% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 3.2%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 2.6%).
BJ's Restaurants Inc. operates a chain of casual dining restaurants across the United States. Its menu features signature deep-dish pizzas, craft beers, handcrafted cocktails, and a wide range of American comfort food. The brand primarily serves family groups, friend gatherings, and casual diners seeking affordable, high-quality meals in a relaxed, welcoming in-store environment.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
BJRI vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $355.4M | $708.5M |
| Net Profit | $12.6M | $135.1M |
| Gross Margin | 74.5% | — |
| Operating Margin | 3.1% | 21.6% |
| Net Margin | 3.6% | 19.1% |
| Revenue YoY | 3.2% | 32.0% |
| Net Profit YoY | -24.2% | 15.5% |
| EPS (diluted) | $0.58 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $355.4M | $708.5M | ||
| Q3 25 | $365.6M | $659.9M | ||
| Q2 25 | $348.0M | $603.3M | ||
| Q1 25 | — | $558.6M | ||
| Q4 24 | $325.7M | $536.6M | ||
| Q3 24 | $349.9M | $533.3M | ||
| Q2 24 | $337.3M | $528.1M | ||
| Q1 24 | — | $511.0M |
| Q4 25 | $12.6M | $135.1M | ||
| Q3 25 | $22.2M | $111.1M | ||
| Q2 25 | $13.5M | $90.3M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | $-2.9M | $117.0M | ||
| Q3 24 | $17.2M | $96.4M | ||
| Q2 24 | $7.7M | $88.4M | ||
| Q1 24 | — | $102.6M |
| Q4 25 | 74.5% | — | ||
| Q3 25 | 75.2% | — | ||
| Q2 25 | 75.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 73.4% | — | ||
| Q3 24 | 74.3% | — | ||
| Q2 24 | 74.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | 3.1% | 21.6% | ||
| Q3 25 | 5.8% | 21.5% | ||
| Q2 25 | 4.3% | 20.9% | ||
| Q1 25 | — | 20.3% | ||
| Q4 24 | -0.8% | 23.4% | ||
| Q3 24 | 3.8% | 21.1% | ||
| Q2 24 | 2.4% | 19.9% | ||
| Q1 24 | — | 20.4% |
| Q4 25 | 3.6% | 19.1% | ||
| Q3 25 | 6.1% | 16.8% | ||
| Q2 25 | 3.9% | 15.0% | ||
| Q1 25 | — | 20.5% | ||
| Q4 24 | -0.9% | 21.8% | ||
| Q3 24 | 4.9% | 18.1% | ||
| Q2 24 | 2.3% | 16.7% | ||
| Q1 24 | — | 20.1% |
| Q4 25 | $0.58 | $4.65 | ||
| Q3 25 | $0.97 | $3.86 | ||
| Q2 25 | $0.58 | $3.10 | ||
| Q1 25 | — | $3.67 | ||
| Q4 24 | $-0.13 | $3.67 | ||
| Q3 24 | $0.72 | $3.01 | ||
| Q2 24 | $0.32 | $2.75 | ||
| Q1 24 | — | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.8M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $366.2M | $459.1M |
| Total Assets | $1.0B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.8M | $497.0M | ||
| Q3 25 | $26.0M | $285.4M | ||
| Q2 25 | $19.0M | $46.3M | ||
| Q1 25 | — | $441.4M | ||
| Q4 24 | $18.4M | $669.4M | ||
| Q3 24 | $16.2M | $656.9M | ||
| Q2 24 | $18.8M | $510.9M | ||
| Q1 24 | — | $407.0M |
| Q4 25 | — | — | ||
| Q3 25 | $60.5M | — | ||
| Q2 25 | $85.5M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $66.5M | — | ||
| Q3 24 | $63.5M | — | ||
| Q2 24 | $58.0M | — | ||
| Q1 24 | — | — |
| Q4 25 | $366.2M | $459.1M | ||
| Q3 25 | $386.6M | $293.6M | ||
| Q2 25 | $371.5M | $172.4M | ||
| Q1 25 | — | $593.6M | ||
| Q4 24 | $376.2M | $825.5M | ||
| Q3 24 | $386.5M | $881.4M | ||
| Q2 24 | $375.4M | $763.6M | ||
| Q1 24 | — | $671.5M |
| Q4 25 | $1.0B | $2.0B | ||
| Q3 25 | $1.0B | $1.8B | ||
| Q2 25 | $1.0B | $1.6B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | $1.0B | $2.1B | ||
| Q3 24 | $1.0B | $2.1B | ||
| Q2 24 | $1.0B | $1.9B | ||
| Q1 24 | — | $1.8B |
| Q4 25 | — | — | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $192.7M | ||
| Q3 25 | $62.3M | $246.2M | ||
| Q2 25 | $4.6M | $148.5M | ||
| Q1 25 | — | $125.8M | ||
| Q4 24 | $27.3M | $190.7M | ||
| Q3 24 | $20.2M | $149.1M | ||
| Q2 24 | $22.3M | $116.4M | ||
| Q1 24 | — | $152.7M |
| Q4 25 | — | $188.1M | ||
| Q3 25 | $41.9M | $235.5M | ||
| Q2 25 | $-12.1M | $142.4M | ||
| Q1 25 | — | $115.8M | ||
| Q4 24 | $7.6M | $183.0M | ||
| Q3 24 | $735.0K | $138.5M | ||
| Q2 24 | $448.0K | $103.5M | ||
| Q1 24 | — | $147.2M |
| Q4 25 | — | 26.6% | ||
| Q3 25 | 11.5% | 35.7% | ||
| Q2 25 | -3.5% | 23.6% | ||
| Q1 25 | — | 20.7% | ||
| Q4 24 | 2.3% | 34.1% | ||
| Q3 24 | 0.2% | 26.0% | ||
| Q2 24 | 0.1% | 19.6% | ||
| Q1 24 | — | 28.8% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | 5.6% | 1.6% | ||
| Q2 25 | 4.8% | 1.0% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | 6.0% | 1.4% | ||
| Q3 24 | 5.6% | 2.0% | ||
| Q2 24 | 6.5% | 2.4% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | — | 1.43× | ||
| Q3 25 | 2.80× | 2.22× | ||
| Q2 25 | 0.34× | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | 1.18× | 1.55× | ||
| Q2 24 | 2.89× | 1.32× | ||
| Q1 24 | — | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BJRI
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
